Investment case
ImmunoGen, Inc.
IMRX · 2 developments mapped · last assessed 2026-08-27
Market Ontology has mapped 2 macro, policy, and market developments to ImmunoGen, Inc. since 2026-08-27. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for IMRX yet, so no modelled value is shown. The IMRX valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run IMRX on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Open question
FDA Approves Revolution Medicines' RASONQUE as First Broad RAS Inhibitor
Indirect competitive pressure or potential partnership opportunities in the broader oncology/targeted therapy space, depending on pipeline overlap or strategic shifts.
· Moves competitive landscape for pipeline assets, market share assumptions for existing or future products
What changed, by assumption
- 2026-08-27FDA Approves Revolution Medicines' RASONQUE as First Broad RAS Inhibitor
- 2026-08-27FDA Approves Revolution Medicines RASONQUE for Metastatic Pancreatic Adenocarcinoma
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-08-27 | FDA Approves Revolution Medicines' RASONQUE as First Broad RAS Inhibitor | watch | 3-12m | 0.30 |
| 2026-08-27 | FDA Approves Revolution Medicines RASONQUE for Metastatic Pancreatic Adenocarcinoma | watch | 3-12m | 0.20 |